Role of aldo-keto reductases in development of prostate and breast cancer

Frontiers in Bioscience

Volumn 11, Issue SUPPL. 2, 2006, Pages 2767-2773

  Jin, Junfei ^a,b   Krishack, Paulette ^c   Cao, Deliang ^c  

^a MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aflatoxin B1; Aldo Keto Reductase; Aldose Reductase Like 1 Aldo Keto Reductase Family 1 member 10; Anti tumor agents; Breast Cancer; Carbonyl Metabolism; Hepatocellular Carcinoma; Lung Cancer; Prostate Cancer; Review

Indexed keywords

MAMMALIA; RODENTIA;

EID: 33744459971     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/2006     Document Type: Review

References (58)

1. Penning, T. M.: AKR1B10: a new diagnostic marker of non-small cell lung carcinoma in smokers. Clin Cancer Res 11, 1687-90 (2005)
2. Jez, J. M., T. G. Flynn & T. M. Penning: A new nomenclature for the aldo-keto reductase superfamily. Biochem Pharmacol 54, 639-47 (1997)
3. Forrest, G. L. & B. Gonzalez: Carbonyl reductase. Chem Biol Interact 129, 21-40 (2000)
4. Kawai, K., M. Jijiwa, Y. Shimono, K. Kurokawa, Y. Murakumo, M. Ichihara & M. Takahashi: Establishment and characterization of mouse mammary carcinoma cell lines expressing RET with a multiple endocrine neoplasia 2A mutation. Cancer Sci 94, 992-7 (2003)
5. Zeindl-Eberhart, E., S. Klugbauer, N. Dimitrijevic, P. R. Jungblut, S. Lamer & H. M. Rabes: Proteome analysis of rat hepatomas: carcinogen-dependent tumor-associated protein variants. Electrophoresis 22, 3009-18 (2001)
6. Bohren, K. M., O. A. Barski & K. H. Gabbay: Characterization of a novel murine aldo-keto reductase. Adv Exp Med Biol 414, 455-64 (1997)
7. Vergnes, L., J. Phan, A. Stolz & K. Reue: A cluster of eight hydroxysteroid dehydrogenase genes belonging to the aldo-keto reductase supergene family on mouse chromosome 13. J Lipid Res 44, 503-11 (2003)
8. Kaneko, M., L. Bucciarelli, Y. C. Hwang, L. Lee, S. F. Yan, A. M. Schmidt & R. Ramasamy: Aldose reductase and AGE-RAGE pathways: key players in myocardial ischemic injury. Ann N Y Acad Sci 1043, 702-9 (2005)
9. Srivastava, S. K., K. V. Ramana & A. Bhatnagar: Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options. Endocr Rev 26, 380-92 (2005)
10. Petrash, J. M.: All in the family: aldose reductase and closely related aldo-keto reductases. Cell Mol Life Sci 32, 737-49 (2004).
11. Burg, M. B.: Molecular basis of osmotic regulation. Am J Physiol 268, F983-96 (1995)
12. Grimshaw, C. E.: Aldose reductase: model for a new paradigm of enzymic perfection in detoxification catalysts. Biochemistry 31, 10139-45 (1992)
13. Licht, T., F. Herrmann, M. M. Gottesman & I. Pastan: In vivo drug-selectable genes: a new concept in gene therapy. Stem Cells 15, 104-11 (1997)
14. Hayes, J. D., R. McLeod, E. M. Ellis, D. J. Pulford, L. S. Ireland, L. I. McLellan, D. J. Judah, M. M. Manson & G. E. Neal: Regulation of glutathione S-transferases and aldehyde reductase by chemoprotectors: studies of mechanisms responsible for inducible resistance to aflatoxin B1. IARC Sci Publ 175-87 (1996)
15. Steckelbroeck, S., Y. Jin, S. Gopishetty, B. Oyesanmi & T. M. Penning: Human cytosolic 3alpha-hydroxysteroid dehydrogenases of the aldo-keto reductase superfamily display significant 3beta-hydroxysteroid dehydrogenase activity: implications for steroid hormone metabolism and action. J Biol Chem 279, 10784-95 (2004)
16. Yasuda, N., K. Fujino, T. Shiraji, F. Nambu & K. Kondo: Effects of steroid 5alpha-reductase inhibitor ONO-9302 and anti-androgen allylestrenol on the prostatic growth, and plasma and prostatic hormone levels in rats. Jpn J Pharmacol 74, 243-52 (1997)
17. Zeindl-Eberhart, E., P. R. Jungblut, A. Otto & H. M. Rabes: Identification of tumor-associated protein variants during rat hepatocarcinogenesis. Aldose reductase. J Biol Chem 269, 14589-94 (1994)
18. Zeindl-Eberhart, E., P. Jungblut & H. M. Rabes: Expression of tumor-associated protein variants in chemically induced rat hepatomas and transformed rat liver cell lines determined by two-dimensional electrophoresis. Electrophoresis 15, 372-81 (1994)
19. Takahashi, M., J. Fujii, E. Miyoshi, A. Hoshi & N. Taniguchi: Elevation of aldose reductase gene expression in rat primary hepatoma and hepatoma cell lines: implication in detoxification of cytotoxic aldehydes. Int J Cancer 62, 749-54 (1995)
20. Takahashi, M., A. Hoshi, J. Fujii, E. Miyoshi, T. Kasahara, K. Suzuki, K. Aozasa & N. Taniguchi: Induction of aldose reductase gene expression in LEC rats during the development of the hereditary hepatitis and hepatoma. Jpn J Cancer Res 87, 337-41 (1996)
21. Cao, D., S. T. Fan & S. S. Chung: Identification and characterization of a novel human aldose reductase-like gene. J Biol Chem 273, 11429-35 (1998)
22. Lee, K. W., B. C. Ko, Z. Jiang, D. Cao & S. S. Chung: Overexpression of aldose reductase in liver cancers may contribute to drug resistance. Anticancer Drugs 12, 129-32 (2001)
23. Zeindl-Eberhart, E., S. Haraida, S. Liebmann, P. R. Jungblut, S. Lamer, D. Mayer, G. Jager, S. Chung & H. M. Rabes: Detection and identification of tumor-associated protein variants in human hepatocellular carcinomas. Hepatology 39, 540-9 (2004)
24. Scuric, Z., S. C. Stain, W. F. Anderson & J. J. Hwang: New member of aldose reductase family proteins overexpressed in human hepatocellular carcinoma. Hepatology 27, 943-50 (1998)
25. Fukumoto, S., N. Yamauchi, H. Moriguchi, Y. Hippo, A. Watanabe, J. Shibahara, H. Taniguchi, S. Ishikawa, H. Ito, S. Yamamoto, H. Iwanari, M. Hironaka, Y. Ishikawa, T. Niki, Y. Sohara, T. Kodama, M. Nishimura, M. Fukayama, H. Dosaka-Akita & H. Aburatani: Overexpression of the aldo-keto reductase family protein AKR1B10 is highly correlated with smokers' non-small cell lung carcinomas. Clin Cancer Res 11, 1776-85 (2005)
26. Chambon, P.: A decade of molecular biology of retinoic acid receptors. Faseb J 10, 940-54 (1996)
27. Eaton, D. L. & E. P. Gallagher: Mechanisms of aflatoxin carcinogenesis. Annu Rev Pharmacol Toxicol 34, 135-72 (1994)
28. Knight, L. P., T. Primiano, J. D. Groopman, T. W. Kensler & T. R. Sutter: cDNA cloning, expression and activity of a second human aflatoxin B1-metabolizing member of the aldo-keto reductase superfamily, AKR7A3. Carcinogenesis 20, 1215-23 (1999)
29. McLeod, R., E. M. Ellis, J. R. Arthur, G. E. Neal, D. J. Judah, M. M. Manson & J. D. Hayes: Protection conferred by selenium deficiency against aflatoxin B1 in the rat is associated with the hepatic expression of an aldo-keto reductase and a glutathione S-transferase subunit that metabolize the mycotoxin. Cancer Res 57, 4257-66 (1997)
30. Hinshelwood, A., G. McGarvie & E. Ellis: Characterisation of a novel mouse liver aldo-keto reductase AKR7A5. FEBS Lett 523, 213-8 (2002)
31. Ireland, L. S., D. J. Harrison, G. E. Neal & J. D. Hayes: Molecular cloning, expression and catalytic activity of a human AKR7 member of the aldo-keto reductase superfamily: evidence that the major 2-carboxybenzaldehyde reductase from human liver is a homologue of rat aflatoxin B1-aldehyde reductase. Biochem J 332, 21-34 (1998)
32. Judah, D. J., J. D. Hayes, J. C. Yang, L. Y. Lian, G. C. Roberts, P. B. Farmer, J. H. Lamb & G. E. Neal: A novel aldehyde reductase with activity towards a metabolite of aflatoxin B1 is expressed in rat liver during carcinogenesis and following the administration of an anti-oxidant. Biochem J 292, 13-8 (1993)
33. Ellis, E. M., D. J. Judah, G. E. Neal & J. D. Hayes: An ethoxyquin-inducible aldehyde reductase from rat liver that metabolizes aflatoxin B1 defines a subfamily of aldo-keto reductases. Proc Natl Acad Sci U S A 90, 10350-4 (1993)
34. Hayes, J. D., D. J. Judah, L. I. McLellan, L. A. Kerr, S. D. Peacock & G. E. Neal: Ethoxyquin-induced resistance to aflatoxin B1 in the rat is associated with the expression of a novel alpha-class glutathione S-transferase subunit, Yc2, which possesses high catalytic activity for aflatoxin B1-8,9-epoxide. Biochem J 279, 385-98 (1991)
35. Hayes, J. D., D. J. Judah & G. E. Neal: Resistance to aflatoxin B1 is associated with the expression of a novel aldo-keto reductase which has catalytic activity towards a cytotoxic aldehyde-containing metabolite of the toxin. Cancer Res 53, 3887-94 (1993)
36. Kelly, V. P., E. M. Ellis, M. M. Manson, S. A. Chanas, G. J. Moffat, R. McLeod, D. J. Judah, G. E. Neal & J. D. Hayes: Chemoprevention of aflatoxin B1 hepatocarcinogenesis by coumarin, a natural benzopyrone that is a potent inducer of aflatoxin B1-aldehyde reductase, the glutathione S-transferase A5 and P1 subunits, and NAD(P)H:quinone oxidoreductase in rat liver. Cancer Res 60, 957-69 (2000)
37. Ellis, E. M., D. J. Judah, G. E. Neal, T. O'Connor & J. D. Hayes: Regulation of carbonyl-reducing enzymes in rat liver by chemoprotectors. Cancer Res 56, 2758-66 (1996)
38. Primiano, T., J. A. Gastel, T. W. Kensler & T. R. Sutter: Isolation of cDNAs representing dithiolethione-responsive genes. Carcinogenesis 17, 2297-303 (1996)
39. Lin, H. K., J. M. Jez, B. P. Schlegel, D. M. Peehl, J. A. Pachter & T. M. Penning: Expression and characterization of recombinant type 2 3 alpha-hydroxysteroid dehydrogenase (HSD) from human prostate: demonstration of bifunctional 3 alpha/17 beta-HSD activity and cellular distribution. Mol Endocrinol 11, 1971-84 (1997)
40. Dufort, I., F. Labrie & V. Luu-The: Human types 1 and 3 3 alpha-hydroxysteroid dehydrogenases: differential lability and tissue distribution. J Clin Endocrinol Metab 86, 841-6 (2001)
41. Dufort, I., P. Rheault, X. F. Huang, P. Soucy & V. Luu-The: Characteristics of a highly labile human type 5 17beta-hydroxysteroid dehydrogenase. Endocrinology 140, 568-74 (1999)
42. Khanna, M., K. N. Qin, R. W. Wang & K. C. Cheng: Substrate specificity, gene structure, and tissue-specific distribution of multiple human 3 alpha-hydroxysteroid dehydrogenases. J Biol Chem 270, 20162-8 (1995)
43. Deyashiki, Y., A. Ogasawara, T. Nakayama, M. Nakanishi, Y. Miyabe, K. Sato & A. Hara: Molecular cloning of two human liver 3 alpha-hydroxysteroid/ dihydrodiol dehydrogenase isoenzymes that are identical with chlordecone reductase and bile-acid binder. Biochem J 299, 545-52 (1994)
44. Bennett, M. J., R. H. Albert, J. M. Jez, H. Ma, T. M. Penning & M. Lewis: Steroid recognition and regulation of hormone action: crystal structure of testosterone and NADP+ bound to 3 alpha-hydroxysteroid/dihydrodiol dehydrogenase. Structure 5, 799-812 (1997)
45. Bauman, D. R., S. Steckelbroeck & T. M. Penning: The roles of aldo-keto reductases in steroid hormone action. Drug News Perspect 17, 563-78 (2004)
46. Penning, T. M., Y. Jin, S. Steckelbroeck, T. Lanisnik Rizner & M. Lewis: Structure-function of human 3 alpha-hydroxysteroid dehydrogenases: genes and proteins. Mol Cell Endocrinol 215, 63-72 (2004)
47. Lin, H. K., S. Steckelbroeck, K. M. Fung, A. N. Jones & T. M. Penning: Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostate. Steroids 69, 795-801 (2004)
48. Nishi, N., H. Shoji, H. Miyanaka & T. Nakamura: Androgen-regulated expression of a novel member of the aldo-keto reductase superfamily in regrowing rat prostate. Endocrinology 141, 3194-9 (2000)
49. Ji, Q., L. Chang, D. VanDenBerg, F. Z. Stanczyk & A. Stolz: Selective reduction of AKR1C2 in prostate cancer and its role in DHT metabolism. Prostate 54, 275-89 (2003)
50. Rizner, T. L., H. K. Lin, D. M. Peehl, S. Steckelbroeck, D. R. Bauman & T. M. Penning: Human type 3 3alpha-hydroxysteroid dehydrogenase (aldo-keto reductase 1C2) and androgen metabolism in prostate cells. Endocrinology 144, 2922-32 (2003)
51. Rizner, T. L., H. K. Lin & T. M. Penning: Role of human type 3 3alpha-hydroxysteroid dehydrogenase (AKR1C2) in androgen metabolism of prostate cancer cells. Chem Biol Interact 143-144, 401-9 (2003)
52. Penning, T. M., M. E. Burczynski, J. M. Jez, C. F. Hung, H. K. Lin, H. Ma, M. Moore, N. Palackal & K. Ratnam: Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem J 351, 67-77 (2000)
53. Supanaranond, K., S. Sukarayodhin, M. Tanyakaset, K. Balachandra, D. Jullaksorn, M. Rienkijkarn, N. Hoisanka & S. Tantivanich: The significance of HER-2/neu/c-erbB-2 gene amplification in benign and malignant breast disease. Southeast Asian J Trop Med Public Health 28, 631-40 (1997)
54. Fehm, T., P. Maimonis, S. Weitz, Y. Teramoto, A. Katalinic & W. Jager: Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients. Breast Cancer Res Treat 43, 87-95 (1997)
55. Zhang, D. H., L. K. Tai, L. L. Wong, L. L. Chiu, S. K. Sethi & E. S. Koay: Proteomics study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu positive breast cancer. Mol Cell Proteomics 4, 1686-1696 (2005)
56. Haiman, C. A., S. E. Hankinson, I. De Vivo, C. Guillemette, N. Ishibe, D. J. Hunter & C. Byrne: Polymorphisms in steroid hormone pathway genes and mammographic density. Breast Cancer Res Treat 77, 27-36 (2003)
57. Lord, S. J., W. J. Mack, D. Van Den Berg, M. C. Pike, S. A. Ingles, C. A. Haiman, W. Wang, Y. R. Parisky, H. N. Hodis & G. Ursin: Polymorphisms in genes involved in estrogen and progesterone metabolism and mammographic density changes in women randomized to postmenopausal hormone therapy: results from a pilot study. Breast Cancer Res 7, R336-44 (2005)
58. Lewis, M. J., J. P. Wiebe & J. G. Heathcote: Expression of progesterone metabolizing enzyme genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinoma. BMC Cancer 4, 27-35 (2004)